According to Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), to predict therapeutic response of Iressa® (gefitinib), the use of circulating tumor DNA obtained from a blood sample has been allowed to assess EGFR mutation status in patients where a tumor sample is not an option[13]. Here, EGFR is linked to neoplasm.